ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

KYMR Kymera Therapeutics Inc

37,275
0,975 (2,69%)
Última atualização: 11:08:23
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Kymera Therapeutics Inc KYMR NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,975 2,69% 37,275 11:08:23
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
37,35 36,78 38,21 36,30
mais cotações »

Notícias Recentes

Data Hora Fonte Título
02/05/202408:00GLOBEKymera Therapeutics Announces First Quarter 2024 Financial..
25/04/202408:00GLOBEKymera Therapeutics to Report First Quarter 2024 Financial..
08/04/202408:00GLOBEKymera Therapeutics Announces Scientific Presentations at..
08/03/202412:00GLOBEKymera Therapeutics Presents Preclinical Data for STAT6 and..
28/02/202409:00GLOBEKymera Therapeutics to Participate in Upcoming March..
22/02/202409:00GLOBEKymera Therapeutics Announces Fourth Quarter and Full Year..
15/02/202409:00GLOBEKymera Therapeutics to Report Fourth Quarter and Full Year..
31/01/202409:00GLOBEKymera Therapeutics to Present in Fireside Chat at the..
09/01/202411:17GLOBEKymera Therapeutics Outlines Key 2024 Objectives and..
09/01/202411:15GLOBEKymera Therapeutics Announces Closing of Upsized $275..
05/01/202408:00GLOBEKymera Therapeutics Announces Pricing of $275 Million Public..
04/01/202418:01GLOBEKymera Therapeutics Announces Proposed Public Offering
04/01/202409:00GLOBER&D Day Highlights Kymera’s Immunology Strategy and Emerging..
02/01/202409:00GLOBEKymera Therapeutics to Present at the 42nd Annual J.P...
13/12/202309:00GLOBEKymera Therapeutics to Host Virtual Immunology R&D Day on..
10/12/202323:00GLOBEKymera Therapeutics Presents Interim Results from STAT3..
07/12/202309:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
13/11/202313:00GLOBEKymera Therapeutics Announces Publication of Phase 1 Trial..
02/11/202310:00GLOBEKymera Therapeutics to Present New Clinical Data from the..
02/11/202308:00GLOBEKymera Therapeutics Announces Third Quarter 2023 Financial..
01/11/202308:00GLOBEKymera Therapeutics to Participate in Upcoming November..
27/10/202308:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
26/10/202308:00GLOBEKymera Therapeutics to Report Third Quarter 2023 Financial..
16/10/202308:00GLOBEKymera Therapeutics Presents Preclinical Data Demonstrating..
18/09/202308:00GLOBEKymera Therapeutics Receives U.S. FDA Fast Track Designation..
03/08/202308:00GLOBEKymera Therapeutics Announces Second Quarter 2023 Financial..
27/07/202308:00GLOBEKymera Therapeutics to Report Second Quarter 2023 Financial..
22/06/202310:21DJNKymera Therapeutics Gets Orphan-Drug Status for Leukemia..
22/06/202309:30GLOBEKymera Therapeutics Receives FDA Orphan Drug Designation for..
14/06/202303:30GLOBEKymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD..
09/06/202319:00GLOBEKymera Therapeutics Announces Updated Clinical Data from the..
09/06/202304:00GLOBEKymera Therapeutics Presents Data Demonstrating Superior..
01/06/202308:00GLOBEKymera Therapeutics to Participate in Upcoming June Investor..
22/05/202308:00GLOBEKymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating..
19/05/202308:00GLOBEKymera Therapeutics Doses First Patient in Phase 1 Oncology..
18/05/202308:00GLOBEKymera Therapeutics Presents Clinical Data from the Phase 1..
04/05/202308:00GLOBEKymera Therapeutics Announces First Quarter 2023 Financial..

Seu Histórico Recente

Delayed Upgrade Clock